教員業績データベース |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Prognostic value of pretreatment volume-based quantitative (18)F-FDG PET/CT parameters in patients with malignant pleural mesothelioma. |
掲載誌名 | 正式名:European journal of radiology 略 称:Eur J Radiol ISSNコード:1872-7727(Electronic)0720-048X(Linking) |
掲載区分 | 国外 |
巻・号・頁 | 86,pp.176-183 |
著者・共著者 | Kitajima Kazuhiro, Doi Hiroshi, Kuribayashi Kozo, Hashimoto Masaki, Tsuchitani Tatsuya, Tanooka Masao, Fukushima Kazuhito, Nakano Takashi, Hasegawa Seiki, Hirota Shozo |
発行年月 | 2017/01 |
概要 | PURPOSE:To investigate the relationships between pretreatment volume-based quantitative (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) parameters and overall survival (OS) in patients with malignant pleural mesothelioma (MPM).MATERIALS AND METHODS:We retrospectively reviewed data from 201 MPM patients, of whom 38 underwent surgical resection, and calculated the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), including primary tumors and nodal or distant metastatic lesions, on pretreatment (18)F-FDG PET/CT. Relationships between clinicopathological factors (age, sex, performance status, European Organization for Research and Treatment of Cancer [EORTC]score, histological subtype, TNM stage, and treatment strategy), volume-based quantitative PET/CT parameters, and OS were evaluated using a Cox proportional hazards model and log-rank test.RESULTS:The median follow-up was 15 months (range, 1-96 months; median, 17 months). In a univariate analysis of all patients, older age (p<0.05), high EORTC score (p<0.001), non-epithelioid histological subtype (p<0.001), high T stage (p<0.001), positive N/M status (p<0.05, p<0.001), advanced TNM stage (p<0.001), non-surgical treatment (p<0.001), and high SUVmax (p<0.001), MTV (p<0.001), or TLG (p<0.001) were associated with significantly shorter OS. A multivariate analysis confirmed non-epithelioid subtype (hazard ratio [HR]: 1.69, 95% confidence interval [CI]: 1.14-2.48; p<0.05), non-surgical treatment (HR: 0.58, 95% CI: 0.34-0.95; p<0.05), and high TLG (HR: 1.97, 95% CI: 1.14-3.44; p<0.05) as independent negative predictors.CONCLUSIONS:Pretreatment volume-based quantitative (18)F-FDG PET/CT parameters, especially TLG, could serve as potential surrogate markers for MPM prognosis. |
DOI | 10.1016/j.ejrad.2016.11.019 |
PMID | 28027744 |